• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $AKBA

    Akebia Therapeutics Inc.

    Subscribe to $AKBA
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

    IPO Year: 2014

    Exchange: NASDAQ

    Website: akebia.com

    Peers

    $ARPO
    $ARDX
    $CALT
    $FGEN
    $ISEE
    $TCDA
    $KDNY

    Recent Analyst Ratings for Akebia Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    4/28/2025$7.00Outperform
    Leerink Partners
    4/1/2025$6.00Buy
    Jefferies
    11/29/2023$4.00Buy
    BTIG Research
    8/28/2023$3.75Neutral → Buy
    H.C. Wainwright
    5/31/2023$2.00 → $4.00Neutral → Overweight
    Piper Sandler
    3/31/2022$10.00 → $2.00Buy → Neutral
    H.C. Wainwright
    3/31/2022Buy → Hold
    Needham
    3/31/2022$6.00 → $2.00Buy → Neutral
    Mizuho
    3/31/2022$6.00 → $2.00Overweight → Neutral
    Piper Sandler
    11/11/2021$6.00 → $10.00Buy
    HC Wainwright & Co.
    See more ratings

    Akebia Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Strong initial quarter of Vafseo® (vadadustat) U.S. product launch, with Vafseo net product revenues of $12.0 million in Q1 2025 Total Q1 2025 net product revenues of $55.8 million Bolstered balance sheet and expanded institutional investor ownership through $50 million underwritten public offering of common stock; cash and cash equivalents of $113.4 million as of the end of the quarter Akebia to Host Conference Call at 8:00 a.m. ET on May 8, 2025 CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) --  Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fir

      5/8/25 7:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 148,000 shares of Akebia's common stock on April 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $2.41 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of t

      5/1/25 4:15:00 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 8, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live webcast of the conference ca

      5/1/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

      CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve XOANACYL® (Ferric Citrate as Coordination Complex) for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD). Averoa, a renal-focused biopharmaceutical company, licensed the rights to develop and commercialize ferric citr

      4/3/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 73,325 shares of Akebia's common stock on March 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $1.92 per share, which is equal to the closing price of Akebia's common stock on the grant date. The stock options vest over four years, with 25% of

      4/2/25 4:05:00 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

      CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025. Akebia-supported posters will be displayed at NKF SCM25 during Exhibit Hall hours. Cardiovascular Risk in Patients With DD-CKD Randomized to Vadadustat vs Darbepoetin Alfa With or Without Cardiovascular Disease: Poster: G-284 Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD:

      3/25/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

      CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. ("Akebia") (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of its underwritten public offering (the "Offering") of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. All shares are being offered by Akebia. The gross proceeds to Akebia from the Offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be $50.0 million. In addition, Akebia has granted the underwriters a 30-day option to purchase up to 3,750,000 additional shares of it

      3/19/25 10:17:53 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Announces Proposed Public Offering of Common Stock

      CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. ("Akebia") (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has commenced an underwritten public offering (the "Offering"). All shares are being offered by Akebia. In addition, Akebia expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the Offering at the public offering price, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may

      3/19/25 4:01:00 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

      Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating plan for at least two years Akebia to Host Conference Call at 8:00 a.m. ET on March 13, 2025 CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full year ended December 31, 2024 and recent business highlights. As previously announced, Vafseo® (vadadustat) shipments to customers began Januar

      3/13/25 7:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

      CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, March 13, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live web

      3/6/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akebia Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Butler John P. sold $84,928 worth of shares (46,409 units at $1.83), decreasing direct ownership by 2% to 2,557,921 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      3/4/25 5:05:06 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Chief Medical Officer Burke Steven Keith sold $13,074 worth of shares (7,144 units at $1.83), decreasing direct ownership by 0.88% to 809,090 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      3/4/25 5:04:33 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Butler John P. was granted 701,000 shares and sold $302,925 worth of shares (144,250 units at $2.10), increasing direct ownership by 27% to 2,604,330 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      2/4/25 5:54:18 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Chief Medical Officer Burke Steven Keith was granted 194,900 shares and sold $106,063 worth of shares (50,506 units at $2.10), increasing direct ownership by 21% to 816,234 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      2/4/25 5:53:09 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Chief Accounting Officer Malabre Richard C was granted 85,000 shares and sold $63,424 worth of shares (30,202 units at $2.10), increasing direct ownership by 24% to 280,248 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      2/4/25 5:52:20 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Grund Nicholas was granted 194,900 shares and sold $116,804 worth of shares (55,621 units at $2.10), increasing direct ownership by 46% to 442,579 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      2/4/25 5:51:42 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, CFO, CBO & Treasurer Ostrowski Erik was granted 194,900 shares, increasing direct ownership by 56% to 544,900 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      2/4/25 5:48:18 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Frieson Ron exercised 20,100 shares at a strike of $0.45, increasing direct ownership by 27% to 93,800 units (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      1/22/25 4:06:17 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, CFO, CBO & Treasurer Ostrowski Erik was granted 350,000 shares (SEC Form 4)

      4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      7/2/24 4:31:37 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Ostrowski Erik

      3 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

      6/26/24 5:37:29 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akebia Therapeutics Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

      Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

      3/28/24 10:46:38 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akebia Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Akebia Therapeutics with a new price target

      Leerink Partners initiated coverage of Akebia Therapeutics with a rating of Outperform and set a new price target of $7.00

      4/28/25 8:36:09 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Akebia Therapeutics with a new price target

      Jefferies initiated coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $6.00

      4/1/25 9:03:14 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research resumed coverage on Akebia Therapeutics with a new price target

      BTIG Research resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $4.00

      11/29/23 7:10:25 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Akebia Therapeutics from Neutral to Buy and set a new price target of $3.75

      8/28/23 7:08:12 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Akebia Therapeutics from Neutral to Overweight and set a new price target of $4.00 from $2.00 previously

      5/31/23 8:56:19 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Akebia Therapeutics from Buy to Neutral and set a new price target of $2.00 from $10.00 previously

      3/31/22 8:47:03 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics downgraded by Needham

      Needham downgraded Akebia Therapeutics from Buy to Hold

      3/31/22 8:45:59 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics downgraded by Mizuho with a new price target

      Mizuho downgraded Akebia Therapeutics from Buy to Neutral and set a new price target of $2.00 from $6.00 previously

      3/31/22 7:06:11 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Akebia Therapeutics from Overweight to Neutral and set a new price target of $2.00 from $6.00 previously

      3/31/22 7:05:04 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Akebia Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $10.00 from $6.00 previously

      11/11/21 6:46:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akebia Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, May 8, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live webcast of the conference ca

      5/1/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

      Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating plan for at least two years Akebia to Host Conference Call at 8:00 a.m. ET on March 13, 2025 CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full year ended December 31, 2024 and recent business highlights. As previously announced, Vafseo® (vadadustat) shipments to customers began Januar

      3/13/25 7:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

      CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, March 13, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live web

      3/6/25 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for VafseoVafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System codeAkebia to Host Conference Call at 8:00 a.m. ET on November 7CAMBRIDGE, Mass., Nov. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2024, and recent business highlights.

      11/7/24 7:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

      Akebia to Host Conference Call on November 7, 2024, at 8:00 a.m. EST CAMBRIDGE, Mass., Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, prior to the open of financial markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization

      11/1/24 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

      Vafseo® (vadadustat) Tablets market availability on track for January 2025 TDAPA application submission and WAC pricing announcement for Vafseo complete Second quarter 2024 Auryxia® (ferric citrate) net product revenues of $41.2 millionAkebia to host conference call at 8:00 a.m. ET on August 8 CAMBRIDGE, Mass., Aug. 8, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the second quarter ended June 30, 2024, and recent business highlights. During the quarter, Akebia made significant progress across multiple initiatives related to the commerci

      8/8/24 7:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

      Akebia to Host Conference Call on August 8, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2024, on Thursday, August 8, 2024, prior to the open of financial markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therap

      8/2/24 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

      Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement with CSL Vifor to simplify operational execution and improve economicsAnnounced Vafseo WAC pricing of $1,278 for a 30-day supplySubmitted TDAPA application for Vafseo in June 2024 and expects designation on January 1, 2025Akebia to host investor conference call at 8:00 a.m. ET on July 11, 2024 CAMBRIDGE, Mass., July 11, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced key updates pertaining to the commercial launch of Vafs

      7/11/24 6:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

      Akebia to host conference call at 8:00 a.m. ET on May 9 Vafseo® (vadadustat) tablets FDA approved on March 27, 2024Vafseo launch activities underway with availability expected in January 2025Auryxia® (ferric citrate) net product revenues were $31.0 million for the first quarter 2024, Akebia expects 2024 Auryxia net product revenue growth versus 2023  CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the first quarter ended March 31, 2024. Akebia is launching Vafseo® (vadadustat) tablets, recently approved by the U.S.

      5/9/24 7:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights

      Akebia to Host Conference Call on May 9, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass., May 2, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, prior to the open of financial markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics

      5/2/24 8:30:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akebia Therapeutics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Akebia Therapeutics Inc.

      10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)

      5/8/25 7:29:11 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

      5/8/25 7:04:15 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Akebia Therapeutics Inc.

      SCHEDULE 13G - Akebia Therapeutics, Inc. (0001517022) (Subject)

      4/30/25 10:57:38 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Akebia Therapeutics Inc.

      DEFA14A - Akebia Therapeutics, Inc. (0001517022) (Filer)

      4/29/25 4:06:53 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Akebia Therapeutics Inc.

      DEF 14A - Akebia Therapeutics, Inc. (0001517022) (Filer)

      4/29/25 4:03:58 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Akebia Therapeutics Inc.

      8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

      3/20/25 4:48:17 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Akebia Therapeutics Inc.

      424B5 - Akebia Therapeutics, Inc. (0001517022) (Filer)

      3/20/25 4:44:09 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Akebia Therapeutics Inc.

      424B5 - Akebia Therapeutics, Inc. (0001517022) (Filer)

      3/19/25 4:12:45 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Akebia Therapeutics Inc.

      10-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

      3/13/25 7:27:55 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

      3/13/25 7:08:55 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akebia Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

      CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeut

      1/9/24 8:30:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

      CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt

      11/1/21 8:00:00 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Akebia Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/13/24 4:58:48 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/9/24 4:00:47 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/10/23 1:08:17 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/9/23 10:54:52 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      1/20/23 8:55:07 AM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Akebia Therapeutics Inc.

      SC 13G - Akebia Therapeutics, Inc. (0001517022) (Subject)

      12/19/22 4:10:11 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Akebia Therapeutics Inc.

      SC 13G - Akebia Therapeutics, Inc. (0001517022) (Subject)

      7/8/22 4:56:59 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      6/9/22 2:15:48 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/10/22 1:23:54 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Akebia Therapeutics Inc. (Amendment)

      SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)

      2/9/22 3:16:00 PM ET
      $AKBA
      Biotechnology: Pharmaceutical Preparations
      Health Care